Published in Oncoimmunology on July 01, 2012
A novel probe for the non-invasive detection of tumor-associated inflammation. Oncoimmunology (2013) 1.05
PET imaging of inflammation biomarkers. Theranostics (2013) 1.04
Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol (2016) 0.95
PET Imaging of Tumor-Associated Macrophages with 89Zr-Labeled High-Density Lipoprotein Nanoparticles. J Nucl Med (2015) 0.83
The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis. Br J Radiol (2014) 0.80
Imaging Tumor Necrosis with Ferumoxytol. PLoS One (2015) 0.77
Visualization of the Biological Behavior of Tumor-Associated Macrophages in Living Mice with Colon Cancer Using Multimodal Optical Reporter Gene Imaging. Neoplasia (2016) 0.76
Iron imaging reveals tumor and metastasis macrophage hemosiderin deposits in breast cancer. PLoS One (2017) 0.75
Inflammation and cancer. Nature (2002) 53.78
Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 9.06
CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 8.54
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65
Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev (2006) 4.69
Chronic inflammation and cancer. Oncology (Williston Park) (2002) 3.82
Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res (2010) 2.48
T1 and T2 relaxivity of intracellular and extracellular USPIO at 1.5T and 3T clinical MR scanning. Eur Radiol (2005) 1.69
Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat (2010) 1.64
MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin Cancer Res (2011) 1.40
Quantification of breast tumor microvascular permeability with feruglose-enhanced MR imaging: initial phase II multicenter trial. Radiology (2003) 1.05
Imaging of tumor angiogenesis: current approaches and future prospects. Curr Pharm Des (2006) 1.00
Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 10.57
Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 8.71
CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 8.54
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65
Tumor stroma and regulation of cancer development. Annu Rev Pathol (2006) 6.66
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell (2005) 5.79
Cancer: an inflammatory link. Nature (2004) 3.88
FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell (2010) 3.80
Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res (2007) 3.76
Differential macrophage programming in the tumor microenvironment. Trends Immunol (2012) 3.18
Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev (2008) 2.85
Collagen-based cell migration models in vitro and in vivo. Semin Cell Dev Biol (2009) 2.84
Humoral immunity, inflammation and cancer. Curr Opin Immunol (2007) 2.68
Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res (2010) 2.48
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev (2010) 2.41
The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest (2008) 2.24
Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res (2012) 2.09
Immune microenvironments in solid tumors: new targets for therapy. Genes Dev (2011) 2.08
Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A (2011) 1.97
The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol (2006) 1.95
Polarized immune responses differentially regulate cancer development. Immunol Rev (2008) 1.95
Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med (2003) 1.84
The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. Cancer Res (2005) 1.84
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res (2004) 1.71
Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev (2009) 1.68
The tumor microenvironment: a critical determinant of neoplastic evolution. Eur J Cell Biol (2003) 1.63
B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis. Proc Natl Acad Sci U S A (2011) 1.58
MMP9 potentiates pulmonary metastasis formation. Cancer Cell (2002) 1.57
Inflammation, proteases and cancer. Eur J Cancer (2006) 1.52
MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin Cancer Res (2011) 1.40
Stromal regulation of vessel stability by MMP14 and TGFbeta. Dis Model Mech (2010) 1.35
Type I collagen is a genetic modifier of matrix metalloproteinase 2 in murine skeletal development. Dev Dyn (2007) 1.35
The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia (2010) 1.33
Soluble mediators of inflammation during tumor development. Adv Cancer Res (2005) 1.24
Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res (2007) 1.21
A selective activity-based probe for the papain family cysteine protease dipeptidyl peptidase I/cathepsin C. J Am Chem Soc (2006) 1.09
Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J Immunol (2013) 1.07
Inflaming gastrointestinal oncogenic programming. Cancer Cell (2008) 1.07
Early neoplastic progression is complement independent. Neoplasia (2005) 1.07
Leukocytes as paracrine regulators of metastasis and determinants of organ-specific colonization. Int J Cancer (2011) 1.04
TIMP-1 alters susceptibility to carcinogenesis. Cancer Res (2004) 1.01
Matrix metalloproteinase-2 and -9 expression increases in Mycoplasma-infected airways but is not required for microvascular remodeling. Am J Physiol Lung Cell Mol Physiol (2004) 0.99
Analysis of immune cell infiltrates during squamous carcinoma development. J Investig Dermatol Symp Proc (2006) 0.99
Epithelial carcinogenesis: dynamic interplay between neoplastic cells and their microenvironment. Differentiation (2002) 0.97
RECKing MMP function: implications for cancer development. Trends Cell Biol (2002) 0.96
Delineating protease functions during cancer development. Methods Mol Biol (2009) 0.93
Hu/Mu ProtIn oligonucleotide microarray: dual-species array for profiling protease and protease inhibitor gene expression in tumors and their microenvironment. Mol Cancer Res (2007) 0.91
IKKalpha at the crossroads of inflammation and metastasis. Cell (2007) 0.89
Distinctive features of angiogenesis and lymphangiogenesis determine their functionality during de novo tumor development. Cancer Res (2007) 0.89
Immune cells as anti-cancer therapeutic targets and tools. J Cell Biochem (2007) 0.89
Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response. Cancer Res (2010) 0.89
Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. Genes Dev (2013) 0.87
Development of an optimized activatable MMP-14 targeted SPECT imaging probe. Bioorg Med Chem (2008) 0.86
Protective role of cathepsin L in mouse skin carcinogenesis. Mol Carcinog (2011) 0.86
Dendritic cells, inflammation, and breast cancer. Cancer J (2013) 0.86
Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor. Int J Cancer (2010) 0.83
Three-dimensional visualization of blood and lymphatic vasculature in tissue whole mounts using confocal microscopy. Curr Protoc Cytom (2005) 0.83
Optical imaging of the peri-tumoral inflammatory response in breast cancer. J Transl Med (2009) 0.81
Genetic and cellular mechanisms of oncogenesis. Curr Opin Genet Dev (2008) 0.81
Mammary gland involution as an immunotherapeutic target for postpartum breast cancer. J Mammary Gland Biol Neoplasia (2014) 0.79
Histamine restricts cancer: nothing to sneeze at. Nat Med (2011) 0.78
Myeloid Cells as Targets for Therapy in Solid Tumors. Cancer J (2015) 0.78
Tumor progression and metastasis from genetic to microenvironmental determinants: a workshop of the tumor progression and metastasis NIH study section in honor of Dr. Martin L. Padarathsingh, May 31, 2006, Georgetown, Washington, DC. Cancer Biol Ther (2006) 0.76
AACR Cancer Progress Report 2016. Clin Cancer Res (2016) 0.75
Some DCs are "B"etter. Immunity (2013) 0.75
Poker face no more: cancer recurrence reveals its hand. Nat Med (2013) 0.75
Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer Vaccines. US Oncol (2009) 0.75
Multiplexed immunohistochemistry image analysis using sparse coding. Conf Proc IEEE Eng Med Biol Soc (2017) 0.75